Biosimilar Uptake Has Been Slow but This is Changing  

Navitus is highlighted as a leading example of the accelerating shift toward biosimilar adoption in the U.S., as health plans increasingly recognize biosimilars as a cost-effective alternative to branded biologics. Managed Healthcare Executive explores how evolving payer strategies, including the Navitus formulary approach, are helping drive biosimilar uptake and health care savings.